Close Menu

NEW YORK (360Dx) – Genfit, one of several companies vying to develop a cure for the increasingly prevalent chronic liver disease nonalcoholic steatohepatitis (NASH), said it has successfully completed the feasibility stage in the development of its biomarker-based in vitro diagnostic for the condition.

If proven clinically useful, the noninvasive blood-based test could represent a significant improvement in the diagnosis of NASH, which can currently be definitively diagnosed only through liver biopsy.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.